Overview
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
Status:
Completed
Completed
Trial end date:
2005-09-01
2005-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the safety of subcutaneous (SC) epoetin beta (NeoRecormon) in adults with solid tumors being treated with platinum-based chemotherapy capable of inducing anemia. The anticipated time on study treatment is 16 weeks, and the target sample size is approximately 208 individuals.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheTreatments:
Epoetin Alfa
Criteria
Inclusion Criteria:- Adults at least 18 years of age
- Presence of solid tumor(s)
- Receiving platinum-based therapy capable of inducing anemia
Exclusion Criteria:
- Red blood cell transfusion within 7 days prior to study drug
- Relevant acute or chronic bleeding requiring therapy within 3 months prior to study
drug
- Women who are pregnant or breastfeeding